Tegoprazan‐Containing Versus Proton Pump Inhibitor‐Containing Therapy for First‐Line Eradication of Helicobacter pylori : A Meta‐Analysis of Randomized Controlled Trials
JGH Open · 2025-03 · 9 (3)
DOI: 10.1002/jgh3.70134 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift JGH Open, online erschienen am 12.03.2025. Verfasst von Daniel Martin Simadibrata und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine Universitas Indonesia Jakarta Indonesia. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Concerns have been raised regarding the decreasing success rates of the standard treatment of Helicobacter pylori (proton pump inhibitor (PPI) and two/three antibiotics) and the long‐term effects carried by PPI. Despite conflicting data, Tegoprazan, a potassium‐competitive acid blocker, is hypothesized to be superior to PPI for eradicating H pylori . This systematic review and meta‐analysis aim to determine the superiority of Tegoprazan‐containing therapy to PPI‐containing therapy for H pylori eradication.
Methods
A systematic literature search identified studies published until December 12, 2024, from MEDLINE, EMBASE, SCOPUS, and CENTRAL. The search strategy included the following keywords: “Tegoprazan,” “ Proton Pump Inhibitors,” and “ Helicobacter pylori . ” Only randomized controlled trials (RCTs) that compared the efficacy of Tegoprazan to any PPI were included. Risk of bias assessment was performed using the Cochrane Risk of Bias 2 (RoB2) tool for RCTs. The random‐effect model was used to calculate the pooled risk ratio (RR) and its 95% Confidence Interval (95% CI) from the intention‐to‐treat population.
Results
Six RCTs with low risks of bias were included in this meta‐analysis. All studies included treatment‐naïve patients and compared first‐line H pylori treatment. The overall eradication rates of Tegoprazan‐containing ( N = 1052) versus PPI‐containing therapy ( N = 1058) were 83.37% and 80.06%, respectively (RR 1.045; 95% CI 1.008–1.084; I 2 = 0%). Tegoprazan‐containing therapy demonstrated comparable treatment‐emergent adverse event (TEAE) rates compared to PPI‐containing therapy (46.48% vs. 46.31%; RR 1.026; 95% CI 0.952–1.106; I 2 = 48%).
Conclusion
This meta‐analysis demonstrated that Tegoprazan‐containing therapy is superior to PPI‐containing therapy for first‐line H pylori eradication, with comparable safety profiles.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Medicine Universitas Indonesia Jakarta Indonesia.
- Department of Medicine MetroHealth Medical Center, Case Western Reserve University Cleveland Ohio USA.
- Department of Internal Medicine Weiss Memorial Hospital Chicago Illinois USA.
- Department of Internal Medicine Texas Tech University Health Sciences Center Lubbock Texas USA.
- Digestive Disease Center and Research Institute, Department of Internal Medicine SoonChunHyang University College of Medicine Bucheon South Korea.
- Division of Gastroenterology, Department of Internal Medicine Faculty of Medicine Universitas Indonesia-Ciptomangunkusumo General Hospital Jakarta Indonesia.
ORCID-Profile: Daniel Martin Simadibrata
Zitieren
APA
Simadibrata, D. M., Lesmana, E., Damara, I., Izzatullah, M., Danpanichkul, P., Yoo, H. W., Hong, S. J., & Syam, A. F. (2025). Tegoprazan‐Containing Versus Proton Pump Inhibitor‐Containing Therapy for First‐Line Eradication of Helicobacter pylori : A Meta‐Analysis of Randomized Controlled Trials. JGH Open, 9(3). https://doi.org/10.1002/jgh3.70134
Vancouver
Simadibrata DM, Lesmana E, Damara I, Izzatullah M, Danpanichkul P, Yoo HW, et al. Tegoprazan‐Containing Versus Proton Pump Inhibitor‐Containing Therapy for First‐Line Eradication of Helicobacter pylori : A Meta‐Analysis of Randomized Controlled Trials. JGH Open. 2025;9(3). doi:10.1002/jgh3.70134
BibTeX
@article{Simadibrata2025,
author = {Simadibrata, Daniel Martin and Lesmana, Elvira and Damara, Ivan and Izzatullah, Mochammad and Danpanichkul, Pojsakorn and Yoo, Hae Won and Hong, Su Jin and Syam, Ari Fahrial},
title = {Tegoprazan‐Containing Versus Proton Pump Inhibitor‐Containing Therapy for First‐Line Eradication of Helicobacter pylori : A Meta‐Analysis of Randomized Controlled Trials},
journal = {JGH Open},
year = {2025},
volume = {9},
number = {3},
doi = {10.1002/jgh3.70134}
}
EUVIMED